A Phase 3 interventional study of Vortioxetine 10 mg/day and Vortioxetine 20 mg/day in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Completed at 124 sites in 19 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-08-19.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 4th largest by enrollment, is one of 9 that started in 2016, is one of 31 in phase 3, and was the 33rd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 784 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 2nd largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2016, is one of 21 in phase 3, and was the 26th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vortioxetine 10 mg/day
Drug: Vortioxetine 20 mg/day
Drug: Fluoxetine 20 mg/day
Other: Placebo
Drug page: Vortioxetine
10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Also known as: Brintellix ®, Lu AA21004
Drug page: Vortioxetine
20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Also known as: Brintellix ®, Lu AA21004
Drug page: Fluoxetine
20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Encapsulated tablet
Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
Time frame: From Randomization to Week 8
Change in CDRS-R Total Score During Treatment (at Week 2)
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'.
Time frame: At week 2
Change in CDRS-R Total Score During Treatment (at Week 4)
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
Time frame: At week 4
Change in CDRS-R Total Score During Treatment (at Week 6)
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
Time frame: At week 6
Change in CDRS-R Mood Score
Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression.
Time frame: From randomization to Week 8
Change in CDRS-R Somatic Score
Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression.
Time frame: From Randomization to Week 8
Change in CDRS-R Subjective Score
Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression.
Time frame: From Randomization to Week 8
Change in CDRS-R Behaviour Score
Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression.
Time frame: From Randomization to Week 8
CDRS-R Response
Children Depression Rating Scale - Response: defined as a \>= 50% decrease in CDRS-R total score, calculated as (change from baseline \[Randomization\])/(baseline value - 17).
Time frame: From Randomization to Week 8
CDRS-R Remission
Remission is defined as a CDRS-R total score \<= 28.
Time frame: From Randomization to Week 8
Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents
Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.
Time frame: From randomization to week 8
Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child
The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology.
Time frame: From randomization to Week 8
Parent Global Assessment-Global Improvement (PGA) Score
The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: From Randomization to Week 8
Change in Symbol Digit Modalities Test (SDMT)
The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning).
Time frame: From Randomization to Week 8
Change in Clinical Global Impression Severity of Illness (CGI-S) Score
The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).
Time frame: From Randomization to Week 8
Clinical Global Impression - Global Improvement (CGI-I) Score
The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.
Time frame: From Randomization to Week 8
CGI-S Remission
Remission defined as CGI-S score of 1 or 2.
Time frame: From Randomization to Week 8
Change in Children's Global Assessment Scale (CGAS) Score
The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function.
Time frame: From Randomization to Week 8
Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: From Randomization to Week 8
Change in PedsQL VAS: Sad or Blue (Sadness) Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: From Randomization to Week 8
Change in PedsQL VAS: Angry Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: From Randomization to Week 8
Change in PedsQL VAS: Worry Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: From Randomization to Week 8
Change in PedsQL VAS: Tired (Fatigue) Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: From Randomization to week 8
Change in PedsQL VAS: Pain or Hurt Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Time frame: From Randomization to Week 8
Change in PedsQL VAS Total Average Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.
Time frame: From Randomization to week 8
Change in PedsQL Emotional Distress Summary Average Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.
Time frame: From Randomization to week 8
Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores
PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction.
Time frame: From Randomization to Week 8
Change in PQ-LES-Q Overall Score
PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).
Time frame: From Randomization to Week 8
| Milestone | Single-blind Treatment, Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo |
|---|---|---|---|---|---|
| Started | 784 | 0 | 0 | 0 | 0 |
| Completed | 616 | 0 | 0 | 0 | 0 |
| Not completed | 168 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Not sepcified | 14 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 12 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled not treated | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Do not fulfill rand criteria for dbt | 103 | 0 | 0 | 0 | 0 |
| Milestone | Single-blind Treatment, Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo |
|---|---|---|---|---|---|
| Started | 0 | 147 | 162 | 153 | 154 |
| Completed | 0 | 126 | 140 | 138 | 138 |
| Not completed | 0 | 21 | 22 | 15 | 16 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Other | 0 | 6 | 5 | 6 | 7 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 4 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 3 | 0 | 1 | 2 |
| Withdrew: Adverse event | 0 | 4 | 8 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 | 2 | 1 |
| Withdrew: Enrolled not treated | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 4 | 2 | 0 | 2 |
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo | Vortioxetine Average (Avg. VOR) |
|---|---|---|---|---|---|
| Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment | -17.09 ± 1.27 | -18.94 ± 1.22 | -21.95 ± 1.23 | -18.22 ± 1.22 | -18.01 ± 0.98 |
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in CDRS-R Total Score During Treatment (at Week 2) | -9.58 ± 1.02 | -10.15 ± 0.99 | -10.34 ± 1.00 | -8.83 ± 0.98 |
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in CDRS-R Total Score During Treatment (at Week 4) | -14.32 ± 1.14 | -15.03 ± 1.10 | -16.25 ± 1.11 | -13.71 ± 1.09 |
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in CDRS-R Total Score During Treatment (at Week 6) | -15.43 ± 1.24 | -17.78 ± 1.19 | -19.20 ± 1.2 | -16.71 ± 1.19 |
Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in CDRS-R Mood Score | -5.05 ± 0.40 | -5.47 ± 0.38 | -6.53 ± 0.38 | -5.32 ± 0.38 |
Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in CDRS-R Somatic Score | -5.63 ± 0.46 | -6.03 ± 0.44 | -6.79 ± 0.45 | -5.78 ± 0.44 |
Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in CDRS-R Subjective Score | -2.41 ± 0.22 | -2.63 ± 0.21 | -3.23 ± 0.21 | -2.66 ± 0.21 |
Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in CDRS-R Behaviour Score | -4.32 ± 0.38 | -4.90 ± 0.36 | -5.52 ± 0.37 | -4.73 ± 0.36 |
Children Depression Rating Scale - Response: defined as a \>= 50% decrease in CDRS-R total score, calculated as (change from baseline \[Randomization\])/(baseline value - 17).
| Participants | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| CDRS-R Response | 53 | 60 | 68 | 49 |
Remission is defined as a CDRS-R total score \<= 28.
| Participants | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| CDRS-R Remission | 21 | 24 | 32 | 20 |
Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents | -6.23 ± 0.56 | -6.48 ± 0.54 | -8.00 ± 0.54 | -6.62 ± 0.53 |
The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child | -5.48 ± 0.61 | -5.55 ± 0.59 | -6.30 ± 0.59 | -6.03 ± 0.58 |
The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Parent Global Assessment-Global Improvement (PGA) Score | 2.80 ± 0.10 | 2.74 ± 0.09 | 2.49 ± 0.09 | 2.72 ± 0.09 |
The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning).
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in Symbol Digit Modalities Test (SDMT) | 3.75 ± 1.02 | 2.64 ± 0.98 | 2.69 ± 0.98 | 2.41 ± 0.97 |
The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in Clinical Global Impression Severity of Illness (CGI-S) Score | -1.23 ± 0.10 | -1.38 ± 0.10 | -1.59 ± 0.10 | -1.21 ± 0.10 |
The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Clinical Global Impression - Global Improvement (CGI-I) Score | 2.81 ± 0.10 | 2.69 ± 0.09 | 2.50 ± 0.09 | 2.73 ± 0.09 |
Remission defined as CGI-S score of 1 or 2.
| Participants | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| CGI-S Remission | 26 | 33 | 36 | 24 |
The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in Children's Global Assessment Scale (CGAS) Score | 12.24 ± 1.25 | 13.89 ± 1.20 | 16.43 ± 1.20 | 14.52 ± 1.19 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score | -0.47 ± 0.19 | -0.76 ± 0.18 | -0.78 ± 0.18 | -0.71 ± 0.18 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in PedsQL VAS: Sad or Blue (Sadness) Score | -1.90 ± 0.26 | -1.71 ± 0.25 | -2.45 ± 0.25 | -2.12 ± 0.24 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in PedsQL VAS: Angry Score | -0.51 ± 0.23 | -0.70 ± 0.23 | -1.01 ± 0.23 | -0.59 ± 0.23 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in PedsQL VAS: Worry Score | -0.96 ± 0.25 | -1.17 ± 0.24 | -0.91 ± 0.24 | -1.33 ± 0.24 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in PedsQL VAS: Tired (Fatigue) Score | -1.18 ± 0.29 | -1.40 ± 0.28 | -1.55 ± 0.28 | -1.27 ± 0.28 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in PedsQL VAS: Pain or Hurt Score | -1.12 ± 0.22 | -0.97 ± 0.21 | -0.83 ± 0.21 | -0.76 ± 0.21 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in PedsQL VAS Total Average Score | -1.00 ± 0.17 | -1.13 ± 0.16 | -1.33 ± 0.16 | -1.14 ± 0.16 |
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in PedsQL Emotional Distress Summary Average Score | -0.93 ± 0.18 | -1.09 ± 0.17 | -1.33 ± 0.17 | -1.18 ± 0.17 |
PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction.
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores | 7.62 ± 0.97 | 7.56 ± 0.93 | 9.26 ± 0.94 | 7.06 ± 0.92 |
PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).
| units on a scale | Vortioxetine 10 mg/Day | Vortioxetine 20 mg/Day | Fluoxetine 20 mg/Day, | Placebo |
|---|---|---|---|---|
| Change in PQ-LES-Q Overall Score | 0.54 ± 0.08 | 0.43 ± 0.08 | 0.67 ± 0.08 | 0.51 ± 0.08 |
Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SBT, Placebo | 0/777 (0%) | 13/777 (1.7%) | 128/777 (16.5%) |
| DBT, Vortioxetine 10 mg | 0/147 (0%) | 4/147 (2.7%) | 47/147 (32%) |
| DBT, Vortioxetine 20 mg | 0/161 (0%) | 7/161 (4.3%) | 57/161 (35.4%) |
| DBT, Fluoxetine 20 mg | 0/153 (0%) | 3/153 (2%) | 40/153 (26.1%) |
| DBT, Placebo | 0/154 (0%) | 1/154 (0.6%) | 30/154 (19.5%) |
| Event | SBT, Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo |
|---|---|---|---|---|---|
| Suicidal ideationPsychiatric disorders | 6/777 | 1/147 | 3/161 | 2/153 | 0/154 |
| AppendicitisInfections and infestations | 1/777 | 1/147 | 0/161 | 0/153 | 0/154 |
| Bronchitis viralInfections and infestations | 0/777 | 1/147 | 0/161 | 0/153 | 0/154 |
| GastroenteritisInfections and infestations | 0/777 | 1/147 | 0/161 | 0/153 | 0/154 |
| Head injuryInjury, poisoning and procedural complications | 0/777 | 0/147 | 0/161 | 1/153 | 0/154 |
| Gastrointestinal viral infectionInfections and infestations | 0/777 | 0/147 | 0/161 | 0/153 | 1/154 |
| MeningitisInfections and infestations | 0/777 | 0/147 | 1/161 | 0/153 | 0/154 |
| Pneumonia bacterialInfections and infestations | 0/777 | 0/147 | 1/161 | 0/153 | 0/154 |
| Viral upper respiratory tract infectionInfections and infestations | 0/777 | 0/147 | 1/161 | 0/153 | 0/154 |
| DepressionPsychiatric disorders | 0/777 | 0/147 | 1/161 | 0/153 | 0/154 |
| Event | SBT, Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 28/777 | 21/147 | 31/161 | 10/153 | 7/154 |
| HeadacheNervous system disorders | 65/777 | 23/147 | 20/161 | 10/153 | 12/154 |
| VomitingGastrointestinal disorders | 13/777 | 7/147 | 15/161 | 8/153 | 1/154 |
| DizzinessNervous system disorders | 21/777 | 11/147 | 7/161 | 6/153 | 5/154 |
| NasopharyngitisInfections and infestations | 26/777 | 6/147 | 10/161 | 10/153 | 5/154 |
| DiarrhoeaGastrointestinal disorders | 13/777 | 5/147 | 9/161 | 7/153 | 5/154 |
| Age, Continuous(years) | Single-blind Treatment (SBT), Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 14.7 ± 1.61 | 14.8 ± 1.66 | 14.5 ± 1.63 | 14.8 ± 1.60 | 14.6 ± 1.60 | 14.67 ± 1.62 |
| Sex: Female, Male(Participants) | Single-blind Treatment (SBT), Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 111 | 93 | 97 | 103 | 105 | 509 |
| Male | 57 | 54 | 65 | 50 | 49 | 275 |
| Race (NIH/OMB)(Participants) | Single-blind Treatment (SBT), Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 0 | 4 | 2 | 4 | 13 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 37 | 19 | 19 | 20 | 22 | 117 |
| White | 108 | 108 | 110 | 112 | 106 | 544 |
| More than one race | 15 | 17 | 25 | 17 | 21 | 95 |
| Unknown or Not Reported | 4 | 3 | 4 | 2 | 1 | 14 |
| CDRS-R total score at Enrolment(units on a scale) | Single-blind Treatment (SBT), Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo | Total |
|---|---|---|---|---|---|---|
| Least squares mean | 61.24 ± 10.00 | 64.82 ± 9.38 | 65.29 ± 9.73 | 64.06 ± 8.65 | 64.02 ± 8.96 | 63.85 ± 9.46 |
| CGI-S at Enrolment(units on a scale) | Single-blind Treatment (SBT), Placebo | DBT, Vortioxetine 10 mg | DBT, Vortioxetine 20 mg | DBT, Fluoxetine 20 mg | DBT, Placebo | Total |
|---|---|---|---|---|---|---|
| Least squares mean | 4.82 ± 0.68 | 4.99 ± 0.77 | 5.00 ± 0.71 | 4.97 ± 0.68 | 4.92 ± 0.69 | 4.94 ± 0.71 |
Showing the first 100 of 124 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2016, a primary completion of Jul 2019 and a completion of Jul 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine